GlassScriptPhysician profile
Gianni Moshero
NPI 1164622494
$2,006.32
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21.85 · 2022: $402 · 2023: $1,070 · 2024: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,582.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $534.92 | 2023 | Nalu Neurostimulation System |
| Nevro Corp. | $373.32 | 2022-2023 | Senza |
| Abbott Laboratories | $370.45 | 2023-2024 | Proclaim |
| Painteq LLC | $166.49 | 2023-2024 | Painteq |
| Vertos Medical, INC. | $152.80 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.57 | 2023-2024 | Relistor |
| Protega Pharmaceutials INC | $67.46 | 2023-2024 | Roxybond |
| Collegium Pharmaceutical, INC. | $65.53 | 2024 | Xtampza, Belbuca |
| Biotronik Nro, INC. | $59.70 | 2023-2024 | Biotronik, Prospera |
| Abbvie INC. | $36.59 | 2022-2024 | |
| Travere Therapeutics, INC. | $19.89 | 2021 | |
| Grt US Holding, INC. | $17.54 | 2022 | |
| Valinor Pharma, LLC | $16.68 | 2024 | Movantik |
| Kowa Pharmaceuticals America, INC. | $13.42 | 2022 | |
| Ambu INC. | $1.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gianni Moshero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.